Published in Blood on June 15, 2000
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | NCT00818961
Graft-versus-host disease. Lancet (2009) 8.78
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant (2011) 2.02
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant (2013) 1.25
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood (2005) 1.18
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant (2009) 1.09
Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant (2014) 1.07
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica (2009) 1.04
HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood (2007) 1.00
Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. Proc Natl Acad Sci U S A (2009) 0.86
The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant (2013) 0.85
Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant (2014) 0.77
Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol (2003) 0.76
Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. Bone Marrow Transplant (2017) 0.76
Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. J Clin Med (2015) 0.75
Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease. Biomedicines (2017) 0.75
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 8.32
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Evolutionary families of peptidases. Biochem J (1993) 5.81
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
A simple, easy, and inexpensive method for monitoring ETCO2 through nasal cannulae. Anesthesiology (1987) 4.19
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06
Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant (2001) 4.02
Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell (1986) 3.59
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48
Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med (1989) 3.46
Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant (2001) 3.35
Cord-blood-cell transplantation--a real sleeper? N Engl J Med (1995) 3.29
Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med (1994) 3.26
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Families of serine peptidases. Methods Enzymol (1994) 2.94
A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93
Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood (1994) 2.93
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 2.63
Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60
MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med (1983) 2.53
HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response. J Clin Invest (1975) 2.48
Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48
An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44
Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42
Soft-tissue sarcoma and non-Hodgkin's lymphoma clusters around a municipal solid waste incinerator with high dioxin emission levels. Am J Epidemiol (2000) 2.41
Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet (1996) 2.41